MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Follow-Up Questions
Qui est le CEO de Mediwound Ltd ?
Mr. Ofer Gonen est le Chief Executive Officer de Mediwound Ltd, il a rejoint l'entreprise depuis 2003.
Quelle est la performance du prix de l'action MDWD ?
Le prix actuel de MDWD est de $17.83, il a decreased de 2.67% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Mediwound Ltd ?
Mediwound Ltd appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de Mediwound Ltd ?
La capitalisation boursière actuelle de Mediwound Ltd est de $228.5M
Est-ce que Mediwound Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Mediwound Ltd, y compris 3 achat fort, 8 achat, 1 maintien, 0 vente et 3 vente forte
